title: Ribozyme mediated cleavage of cell-associated isoform of vascular endothelial growth factor inhibits liver metastasis of a pancreatic cancer cell line.
abstract: Stromal angiogenesis is an important factor for progression of malignant neoplasms. We used hammerhead ribozymes against vascular endothelial growth factor (VEGF) gene transcripts to down-regulate cell-associated VEGF189 isoform function in the pancreatic cancer cell line MIA PaCa2. MIA PaCa2 transfected with anti-VEGF189 ribozyme did not show any alteration of growth rate under tissue culture. When the transformants were subcutaneously transplanted, tumour volume of the ribozyme-transfected MIA PaCa2 xenografts was significantly smaller (P<0.01). No metastasis of MIA PaCa2 transfected with anti-VEGF189 was apparent, while disabled ribozyme-transfected MIA PaCa2 showed significant liver metastasis (P<0.05). These results suggested that VEGF189 plays an important role in growth and metastatic potential through alteration of angiogenic balance in cancer.
authors.affiliation: Department of Pathology, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan.
authors.forename: Tetsuji
authors.initials: T
authors.lastname: Tokunaga
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Abe
authors.forename: Takashi
authors.initials: T
authors.lastname: Tsuchida
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Hatanaka
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Oshika
authors.forename: Masashi
authors.initials: M
authors.lastname: Tomisawa
authors.forename: Masumi
authors.initials: M
authors.lastname: Yoshimura
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Ohnishi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kijima
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Yamazaki
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Ueyama
authors.forename: Masato
authors.initials: M
authors.lastname: Nakamura
mesh_terms: D000818:Animals; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors / Q000235:genetics*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics*; D008113:Liver Neoplasms / Q000517:prevention & control* / Q000556:secondary*; D008222:Lymphokines / Q000037:antagonists & inhibitors / Q000235:genetics*; D051379:Mice; D009368:Neoplasm Transplantation; D010190:Pancreatic Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D020033:Protein Isoforms; D016337:RNA, Catalytic / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000378:metabolism; D010959:Tissue Plasminogen Activator / Q000096:biosynthesis; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D020033:Protein Isoforms; D016337:RNA, Catalytic; D012333:RNA, Messenger; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D010959:Tissue Plasminogen Activator